You are here

Microencapsulated Measles Virus Vaccine

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 21896
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1993
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1025 18th Street South
Birmingham, AL 35205
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Zina Moldoveanu
 (205) 930-9387
Business Contact
Phone: () -
Research Institution
N/A
Abstract

The long term objective is to develop a commercial subunit vaccine against MV infection. Because of the high cost of preparing the surface antigens, a means for achieving an enhanced immune response is an important objective and is the focus. Biocompatible and biodegradable microspheres consisting of a copolymer of DL-lactide and glycolide (poly DL-lactide-co-lactide) will be utilized to incorporate MV antigens into small spherical particles (l-l0um). Microspheres containing viral antigens will be used for subcutaneous, intranasal and oral immunization of mice, and the immune response will be evaluated. Another group of mice will be similarly immunized with inactivated virus in solution for comparison. If significant enhancement in the protective immune response is observed using microencapsulated MV antigens, more detailed studies will be pursued subsequently. Studies will also be conducted to understand the mechanism of protection (cellular/antibody mediated) and the duration of such response. Ultimately, a microencapsulated measles virus vaccine will be utilized in clinical field trials for immunoprophylaxis against measles infection.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government